|
Exosomal Drug Delivery
|
5R44CA221487-02
|
$1,000,000
|
SPENCER, WENDY
|
3P BIOTECHNOLOGIES, INC.
|
|
Targeted Therapy for Non Small Cell Lung Carcinoma: Human Phase 1 safety and dose escalation studies
|
5R44CA162629-03
|
$833,374
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
AVGN7, a Novel Gene Therapeutic for Treating Cancer Cachexia
|
5R44CA221539-02
|
$660,235
|
RODGERS, BUEL
|
AAVOGEN, INC.
|
|
Personalized precision dosing of biologic therapies in oncology
|
5R44CA217336-02
|
$720,363
|
MESSMER, BRADLEY
|
ABREOS BIOSCIENCES, INC.
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
2R44CA200161-02A1
|
$1,000,000
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
3R41CA200161-01A1S3
|
$3,000
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
Implantable iontophoresis chemotherapy delivery device for direct infusion of gemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial
|
4R44CA224460-02
|
$1,111,364
|
DAUNCH, WILLIAM
|
ADVANCED CHEMOTHERAPY TECHNOLOGIES, INC.
|
|
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation
|
4R44CA203336-02
|
$659,516
|
AGUILAR-CORDOVA, ESTUARDO
|
ADVANTAGENE, INC
|
|
A Novel Immunotherapy Targeting Cancer Stem Cells for the Treatment of Triple-Negative Breast Cancer
|
1R44CA224835-01A1
|
$298,864
|
PERICLE, FEDERICA
|
AGILVAX, INC.
|
|
Core Support for Cancer Center
|
3P30CA013330-45S1
|
$3,646,138
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Inhibition of Senescence to Increase Cancer Cell Death: A New Paradigm
|
5R01CA077263-19
|
$417,500
|
MCDAID, HAYLEY
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
IDO-Expressing Immunoregulatory Dendritic Cells
|
5R01CA103320-15
|
$307,800
|
MUNN, DAVID
|
AUGUSTA UNIVERSITY
|
|
Chemotherapy-induced MDSCs and antitumor immunity
|
5R01CA215523-02
|
$347,700
|
ZHOU, GANG
|
AUGUSTA UNIVERSITY
|
|
Integrative Molecular Epidemiology of Neurocognitive Outcomes in Acute Lymphoblastic Leukemia
|
1K07CA218362-01A1
|
$166,043
|
BROWN, AUSTIN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Crosstalk between the ER Stress Response and Mitochondrial Fatty Acid Oxidation in MYC-driven Breast Cancer
|
1R37CA228304-01
|
$362,569
|
CHEN, XI
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQ5) Exploring the Biological Distinctions between HIV-related and Endemic Pediatric Kaposi Sarcoma in a Kaposi Sarcoma-Associated Herpesvirus-Endemic Region of Africa
|
5R21CA217137-02
|
$196,947
|
EL-MALLAWANY, NADER
|
BAYLOR COLLEGE OF MEDICINE
|
|
MICROSCALED PROTEOGENOMICS FOR CANCER CLINICAL TRIALS
|
5U01CA214125-02
|
$1,413,657
|
ELLIS, MATTHEW
|
BAYLOR COLLEGE OF MEDICINE
|
|
Preclinical Analyses of NAD Kinase as a Redox Vulnerability for the Treatment of Pancreatic Cancer
|
5R01CA211176-02
|
$362,569
|
ELSEA, SARAH
|
BAYLOR COLLEGE OF MEDICINE
|
|
SPORE in Lymphoma
|
5P50CA126752-12
|
$2,297,796
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S1
|
$118,875
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S2
|
$249,997
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S3
|
$125,004
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-12
|
$3,203,119
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Translational Research in Breast Cancer (SPORE)
|
5P50CA186784-05
|
$2,251,410
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Using Stat3 Signaling Profiles to Understand Chemotherapy Resistance in AML
|
5R01CA175026-05
|
$379,294
|
REDELL, MICHELE
|
BAYLOR COLLEGE OF MEDICINE
|
|
Targeting aberrant promoter DNA methylation for anticancer therapy
|
1R21CA229727-01
|
$182,700
|
SHEN, LANLAN
|
BAYLOR COLLEGE OF MEDICINE
|
|
A novel miR-198 replacement therapy for pancreatic cancer
|
5R01CA183984-04
|
$473,915
|
YAO, QIZHI
|
BAYLOR COLLEGE OF MEDICINE
|
|
MicroRNA Biomarkers for Determining Treatment Response in Colorectal Cancer
|
5R01CA202797-03
|
$349,694
|
GOEL, AJAY
|
BAYLOR RESEARCH INSTITUTE
|
|
Stem Cell/Nanoparticle Constructs for Targeted Ovarian Cancer Therapy
|
3R01CA197359-04S1
|
$68,577
|
BERLIN, JACOB
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Stem Cell/Nanoparticle Constructs for Targeted Ovarian Cancer Therapy
|
5R01CA197359-04
|
$388,875
|
BERLIN, JACOB
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Combating Subclonal Evolution of Resistant Cancer Phenotypes
|
3U54CA209978-03S1
|
$125,000
|
BILD, ANDREA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Combating Subclonal Evolution of Resistant Cancer Phenotypes
|
5U54CA209978-03
|
$2,154,776
|
BILD, ANDREA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
City of Hope Lymphoma SPORE
|
2P50CA107399-11A1
|
$2,500,000
|
FORMAN, STEPHEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Image-guided irradiation safely intensifies HSCT regimen for refractory leukemia
|
5R01CA195519-03
|
$238,425
|
FORMAN, STEPHEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Targeting microRNAs to eradicate leukemia stem cells
|
5R01CA205247-02
|
$450,769
|
KUO, YA-HUEI
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
CD25-mediated feedback control of BCR-signaling and its oncogenic mimics
|
5R01CA213138-02
|
$395,738
|
MUSCHEN, MARKUS
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Reolysin-based combination therapy in relapsed multiple myeloma
|
5R01CA194742-03
|
$574,645
|
PICHIORRI, FLAVIA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination with Intravenous Irinotecan in Patients with Recurrent High Grade Gliomas
|
5R01CA198076-04
|
$546,873
|
PORTNOW, JANA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
2P30CA033572-35
|
$2,543,187
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-34S3
|
$865,000
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-35S1
|
$43,750
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Complex Role of HSF1 in Breast Cancer
|
5R01CA176326-05
|
$355,719
|
CALDERWOOD, STUART
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Advancing treatment outcomes in malignant glioma by integrating immunotherapy and standard of care using genetically engineered mice that recapitulate molecular feature of human glioma
|
1R01CA229784-01
|
$667,694
|
CHAREST, ALAIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
DF/HCC Kidney Cancer SPORE
|
5P50CA101942-14
|
$2,300,000
|
MCDERMOTT, DAVID
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Targeting PML for Leukemia Therapy
|
5R01CA142874-08
|
$457,619
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
BMX-001 as a Therapeutic Agent for Treatment of Multiple Brain Metastases.
|
1R44CA228694-01
|
$300,000
|
SILBERSTEIN, DAVID
|
BIOMIMETIX JV, LLC
|
|
Passive and active targeting of unnatural chemokine fusions for cancer immunotherapies
|
1F32CA220990-01
|
$61,174
|
FANG, TAO
|
BOSTON CHILDREN'S HOSPITAL
|
|
Discovery and targeting of apoptosis resistance mechanisms in high-risk T-ALL
|
5R01CA193651-04
|
$443,296
|
GUTIERREZ, ALEJANDRO
|
BOSTON CHILDREN'S HOSPITAL
|
|
Protective role of Honokiol in preventing c-Met-induced post-transplantation cancer
|
1R01CA222355-01
|
$411,068
|
PAL, SOUMITRO
|
BOSTON CHILDREN'S HOSPITAL
|
|
CXCR3-B-mediated novel growth-inhibitory signals in breast cancer cells
|
1R03CA215926-01A1
|
$88,500
|
PAL, SOUMITRO
|
BOSTON CHILDREN'S HOSPITAL
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|